SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

WorldFinancial

World Liberty Financial (WLFI) is trending as a U.S. House investigation into its $500 million investment deal with a UAE royal ignites a polarized community debate over its political implications and financial integrity. While proponents view the scrutiny as a buying opportunity ahead of anticipated product launches, skeptics dismiss the Trump-linked crypto venture as a "scam," fueling conversations around crypto regulation and market intervention.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending due to ongoing discussions around its Polkadot 2.0 rollout, which includes a pivotal shift to a capped 2.1 billion token supply and the Agile Coretime model designed to enhance network utility. While many express deep frustration over recent price performance, a strong bullish contingent highlights these fundamental upgrades and staking opportunities as a major re-rating catalyst attracting institutional interest.

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical, Risk, Legal Exhibitions and Print & print-related. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity. The Risk segment provides customers with solutions and decision tools that combine public and industry specific content with advanced technology and analytics to assist them in evaluating and predicting risk and enhancing operational efficiency. The Legal segment is a global provider of legal, regulatory and business information and analytics that helps customers increase productivity, improve decision-making and outcomes and advance the rule of law around the world. The Exhibitions segment is an event business, enhancing the effect of face-to-face through data and digital tools. The Print & print-related segment consistent with financial information provided to the board. The company was founded by Albert Edward Reed in 1903 and is headquartered in London, the United Kingdom.

RELX Plc - ADR

RELX is a focal point of discussion as fears of AI disruption from new legal tools cause a sell-off, while a segment of the community views the dip as a prime opportunity to invest in its high-quality, data-moat business, emphasizing its strong AI integration and ongoing share buyback program.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is trending due to its FDA Breakthrough Device Designation for the CellFX nsPFA Cardiac Surgery System and positive clinical data from first-in-human studies. The community is actively discussing the game-changing potential of its nanosecond Pulsed Field Ablation platform technology across multiple medical applications, reinforced by notable insider buying.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after launching a low-cost compounded weight-loss pill, which immediately drew legal threats from major pharmaceutical companies and prompted a swift FDA response and DOJ referral regarding potential regulatory violations. The community is fiercely debating whether this move is a legitimate disruption challenging "big pharma" or an illegal "copycat" action that could lead to significant penalties and impact the company's long-term viability.

BlackRock Institutional Trust Company N.A. - iShares China Large-Cap ETF

iShares China Large-Cap ETF

FXI is actively discussed as investors weigh a significant trade surplus and recent policy support against concerns over manufacturing contraction and a struggling property sector. The community is watching for further clarity from ongoing US-China trade discussions and potential stimulus, which could drive a broader rally in Chinese equities.

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

GHOST CRYPTO is a trending Solana privacy utility token, capturing community attention for its resilience in a down market and recent integration with Solflare. Enthusiasm is high for its upcoming Ghostswap launch and a revenue-sharing model, with many anticipating substantial growth as a key player in the privacy narrative.

Lighter is a decentralized trading platform built for unmatched security and scale. It’s the first exchange to offer verifiable order matching and liquidations while delivering best-in-class performance on par with traditional exchanges.

lighter

LIT (Lighter) is trending as investors debate strong bullish catalysts like a new Indodax listing and mandatory staking creating a supply squeeze against community concerns over its reported Coinbase delisting and upcoming rebrand to HEI.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending after its Q3 earnings miss, cautious 2026 outlook citing weak housing demand, and news of corporate job cuts and a full return-to-office, fueling concerns about a "renovation recession." Community discussions are split between bearish sentiment over macroeconomic headwinds and bullish views on its long-term Pro strategy and digital investments creating a "buy the dip" opportunity.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

ALMU is trending as its patented technology for integrating high-performance compound semiconductors on large silicon wafers is gaining significant attention as a game-changer for energy-efficient AI optical interconnects, advanced mobile sensors, and quantum computing. Community chatter focuses on the company's low-float and near-term commercialization pivot, with investors eagerly anticipating strategic partnerships and design wins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The patents issued cover critical aspects of Glucotrack’s implantable CBGM technology.</li><li>Unlike conventional CGM systems that sample glucose from interstitial fluid, Glucotrack’s device measures glucose directly from blood.</li><li>The long-term, fully implantable design offers more convenient option for diabetes management.</li></ul>Glucotrack, Inc. (GCTK) announced on Thursday that it has secured three new U.S. patents for its continuous blood glucose monitoring (CBGM) platform.&nbsp;The patents are expected to boost the company’s intellectual property portfolio as it moves its long-term implantable monitoring system closer to commercialization.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/GCTK">Glucotrack stock</a> traded over 12% higher in Thursday’s premarket.&nbsp;<h2 class="st-heading-2">New Patents Strengthen IP</h2>The US Patent and Trademark Office issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258, covering critical aspects of Glucotrack’s implantable CBGM technology.The patents protect innovations in sensor chemistry, intravascular lead design, and low-power electronics, all integral to the company’s implantable system.On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day and message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Clinical And Practical Significance</h2>Unlike conventional CGM systems that sample glucose from interstitial fluid, Glucotrack’s device measures glucose directly from blood. This approach is expected to provide near real-time readings, eliminating the lag commonly seen with subcutaneous sensors.&nbsp;<blockquote>“Securing our intellectual property is fundamental to our strategy as we advance our fully implantable, long-term sensor through further clinical testing and toward commercialization.”-Paul V. Goode, President and CEO, Glucotrack</blockquote>The long-term, fully implantable design also aims to reduce patient burden and improve adherence, offering a potentially more convenient option for diabetes management.Glucotrack’s CBGM is a fully implantable device that tracks blood sugar continuously for up to three years. It does not require any wearable parts on the body and needs very little calibration.&nbsp;GCTK stock has declined by over 97% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-guts-stock-fell-revita-post-glp1-data/cmyig4sR4KA">Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A young girl suffering from diabetes type 1, squeezes air bubbles out of her catheter.

Why Did Glucotrack Stock Surge 12% Pre-Market Today?

The company has received patents for its continuous blood glucose monitoring system.

Equity

Glucotrack Inc. (GCTK), a medical technology company specializing in diabetes management solutions, attracted significant investor interest after its shares rose by over 144% on Friday afternoon.&nbsp;On Thursday, the company announced a new financing arrangement with Sixth Borough Capital Fund LP. This agreement could provide the company with up to $20 million in equity capital over the next two years, depending on various regulatory and market conditions.On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/GCTK">Glucotrack stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume levels also shifted to ‘extremely high’ from ‘low’ levels in the last 24 hours.<figure class="image"><img style="aspect-ratio:942/113;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_12_133920_png_26d362bae8.webp" alt="GCTK’s Sentiment Meter and Message Volume as of 01:30 p.m. ET on Sep. 12, 2025 | Source: Stocktwits" width="942" height="113"><figcaption>GCTK’s Sentiment Meter and Message Volume as of 01:30 p.m. ET on Sep. 12, 2025 | Source: Stocktwits</figcaption></figure>The stock experienced a 1,800% surge in user message count as of Friday morning. Stocktwits users commended the investment move.&nbsp;<stembedurl>https://stocktwits.com/HUBC1/message/628487656</stembedurl><stembedurl>https://stocktwits.com/ArdentInvestor/message/628487338</stembedurl>The deal includes a purchase agreement and a related registration rights agreement. The agreement grants Glucotrack the right, but not the obligation, to issue and sell shares of its common stock valued at up to $20 million. This offering can be executed incrementally, at the company's discretion, within a 24-month window following the commencement date.This financing vehicle provides Glucotrack with a flexible means to raise capital when needed, enabling it to support product development, commercialization, or general operations.&nbsp;For the second quarter, the company’s net loss increased to $4.75 million, compared to a loss of $4.48 million in the same period last year. Cash and equivalents as of June 30 totaled $9.5 million.&nbsp;Glucotrack stock has lost over 97% of its value year-to-date and 99% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/opendoor-chairman-keith-rabois-plans-massive-layoffs/chw8v8XRdDA">Opendoor Chairman Keith Rabois Plans Massive Layoffs: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Glucotrack Stock Just Rose Over 123% Today: Here’s An Important Update

Glucotrack announced a new financing arrangement with Sixth Borough Capital Fund LP on Thursday.

Retail chatter spiked last week as investors piled into three healthcare stocks: GlucoTrack, Sarepta Therapeutics, and TNF Pharmaceuticals, which recorded the highest increases in message volume among healthcare names on Stocktwits.GlucoTrack (GCTK)GlucoTrack posted the highest increase in retail chatter, with message volume surging 3,700% over the past seven days. As of late Sunday, sentiment remained ‘bullish’ among retail traders.On July 8, the company announced the repurchase of over 90% of its Series A Warrants, funded with cash on hand.&nbsp;The move followed last month’s disclosure of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glucotrack-announces-positive-results-from-implantable-blood-glucose-monitor-study/chmJoJwRREo">positive results</a> from its first-in-human clinical study of its continuous blood glucose monitor (CBGM).The implantable device demonstrated 99% data capture, strong accuracy, and no serious adverse events. Designed for a three-year lifespan, the CBGM measures blood glucose directly, not interstitial fluid, and requires no on-body wearable.&nbsp;A long-term feasibility study is expected to launch in Q3 2025.<a href="https://stocktwits.com/symbol/GCTK">GCTK’s stock</a> has declined 98.5% so far in 2025.Sarepta Therapeutics (SRPT)Sarepta saw a 1,991% increase in message volume over the past week, with sentiment remaining ‘extremely bullish’ as of late Sunday, despite mounting regulatory concerns.On July 19, shares plunged over 26% in midday trading after FDA Commissioner Marty Makary said the agency is&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/fda-taking-a-hard-look-to-at-whether-sarepta-gene-therapy-elevidys-should-remain-on-the-market/ch8kDByR5qt">“taking a hard look”</a> at whether Sarepta’s gene therapy, Elevidys, should stay on the market.The company disclosed a third patient death on July 18, involving a 51-year-old participant in a limb-girdle muscular dystrophy trial using a similar viral vector to Elevidys. Two earlier deaths were already under FDA investigation. Reuters reported the agency plans to request a voluntary halt to Elevidys' shipments.Amid the fallout,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">analysts criticized Sarepta</a> for not disclosing the fatality earlier, particularly during a recent business update where it announced a 500-job layoff and $400 million in cost cuts.&nbsp;The company has since paused shipments to non-ambulatory patients and&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-surges-after-hours-as-it-slashes-500-jobs-amid-fda-black-box-warning-for-gene-therapy-retail-eyes-rebound/ch8KR0HR5oM">agreed to a black box warning</a> for Elevidys, citing the risk of acute liver failure.<a href="https://stocktwits.com/symbol/SRPT">SRPT’s stock</a> has declined 88.7% so far in 2025.TNF Pharmaceuticals (TNFA)TNF Pharma recorded a 1,900% rise in message volume over the past seven days on Stocktwits, with sentiment labeled ‘extremely bullish’ as of late Sunday.Although there was no specific news catalyst driving the buzz last week, the momentum has been strong since last month when TNFA announced a Compassionate Use collaboration with the DADA2 Foundation to study isomyosamine as a treatment for DADA2, a rare pediatric autoinflammatory disorder.In April,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tnf-pharmaceuticals-to-use-ai-to-recruit-patients/chQSz8ARbXp">TNFA partnered with Renova Health</a> to apply AI and machine learning to optimize patient recruitment. The company is analyzing data from 30,000 patients to identify high-risk cohorts, particularly for interventions related to inflammation and side effects of GLP-1 therapy.TNFA’s pipeline includes two drug platforms: isomyosamine, which regulates inflammatory pathways, and Supera-CBD, which targets chronic pain, addiction, and epilepsy.<a href="https://stocktwits.com/symbol/TNFA">TNFA’s stock</a> has declined 92.4% so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amazon-stealthily-hiked-prices-on-everyday-essentials-as-trump-tariffs-bit-report/ch8qvlTR5Ae">Amazon Stealthily Hiked Prices On Everyday Essentials As Trump Tariffs Bit: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

GlucoTrack (GCTK), Sarepta Therapeutics (SRPT), and TNF Pharmaceuticals (TNFA) recorded the highest increases in message volume among healthcare names on Stocktwits. (Photo credit: Getty Images)

GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why

GlucoTrack repurchased over 90% of its Series A warrants, while Sarepta disclosed a third patient death, suspended Elevidys shipments, and added a black-box warning amid FDA scrutiny.

Shares of Glucotrack, Inc. (GCTK) traded 32% higher on Wednesday afternoon after the company announced that its first-in-human clinical study for its investigational continuous blood glucose monitor (CBGM) yielded positive results.The medical device company’s CBGM demonstrated excellent accuracy, a 99% data capture rate, and no procedure or device-related serious adverse events, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://glucotrack.com/glucotrack-and-onetwo-analytics-present-positive-final-results-of-first-in-human-study-for-continuous-blood-glucose-monitor-at-american-diabetes-associations-85th-scientific-sessions/">said</a>.Glucotrack’s CBGM is a long-term, implantable system that continually measures glucose from blood rather than interstitial fluid with a sensor designed for a 3-year life and no on-body wearable component.It aims to eliminate the lag time associated with traditional continuous glucose monitoring systems and is connected to subcutaneous electronics that communicate with a mobile application.The in-human study for the CBGM was conducted between Dec. 13, 2024, and Jan. 31, 2025, and included ten participants with either Type 1 or Type 2 diabetes who were on intensive insulin therapy.The insertion and removal procedures were performed by interventional cardiologists.Following the device placement, each participant underwent inpatient observation for 4 days. During this period, frequent blood sampling and glucose tolerance tests were conducted to assess device performance.The system remained in place throughout the study period and was removed successfully at study completion, with patients then followed for 7 days post-removal.Glucotrack now expects to initiate a long-term early feasibility study in Q3 2025, which will evaluate safety and performance of the monitor over an extended period.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GCTK">GCTK</a> soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours to its highest levels in 3 months while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_25_at_12_52_09_PM_png_991ddcc4e4.webp" alt="GCTK's Sentiment Meter and Message Volume as of 12:50 p.m. ET on June 25, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>GCTK's Sentiment Meter and Message Volume as of 12:50 p.m. ET on June 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for Glucotrack being approached by big pharmaceutical companies for either purchase or partnerships following the news.<stembedurl>https://stocktwits.com/Barrister/message/618976594</stembedurl>GCTK stock is down by about 98% this year and has erased nearly all of its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/sarepta-stock-slumps-after-fda-opens-probe-into-patient-death-analyst-sounds-alarm/chmJnVnRREn">Sarepta Stock Slumps After FDA Opens Probe Into Patient Death, Analyst Sounds Alarm</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A woman holds an insulin pen with an exposed injection needle. Photo: Hannes P. Albert/dpa (Photo by Hannes P Albert/picture alliance via Getty Images)

Glucotrack Announces Positive Results From Its Implantable Blood Glucose Monitor Study: Retail Sentiment Hits 3-Month High

The company’s continuous blood glucose monitor demonstrated excellent accuracy, a 99% data capture rate, and no procedure or device-related serious adverse events, the company said.

Regencell Bioscience Holdings Ltd (3,500% Jump in Message Volume)Hong Kong-based Regencell focuses on traditional Chinese medicine for neurocognitive disorders, particularly ADHD and autism. Reports suggest its recent rally was fueled by insider buying, with insiders owning 81% of the company.&nbsp;However, a Stocktwits&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rgc-stock-more-than-triples-this-year/ch7KEpeRbcl">poll</a> indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk.&nbsp;The stock has surged 1,054% this year.GlucoTrack Inc. (2,800% Jump in Message Volume)GlucoTrack develops non-invasive glucose monitoring devices. It announced that safety and performance data from its first-in-human trial of a long-term continuous blood glucose monitoring (CBGM) system will be presented at the 2025 ATTD conference.&nbsp;CEO Paul V. Goode highlighted its potential for real-time glucose monitoring without on-body wearables, calling it a transformative step in diabetes management.&nbsp;GlucoTrack stock is down over 96% year-to-date (YTD).TC Biopharm (Holdings) Plc (1,300% Jump in Message Volume)TC Biopharm&nbsp;<a href="https://stocktwits.com/symbol/TCBP">received</a> a Nasdaq delisting notice due to its share price falling below $1. Trading will be suspended on Monday, with its American depository shares expected to move to OTC Markets.&nbsp;The company is also shifting to a contract development and manufacturing organization (CDMO) model, cutting about 50% of its workforce to reduce operational burn by 55%. This is projected to save $2.1 million in 2025 and $4.2 million annually.&nbsp;The stock is down over 95% YTD.AbbVie Inc. (700% Jump in Message Volume)Erste Group upgraded AbbVie to ‘Buy’ from ‘Hold’, according to The Fly, citing strong sales growth projections through 2029, supported by upcoming product launches. The research firm expects earnings per share (EPS) to rise significantly in 2025, ranging from $12.12 to $12.32.&nbsp;AbbVie recently agreed to acquire a next-gen obesity drug from Denmark-based Gubra A/S for up to $2.2 billion, boosting sentiment.&nbsp;The stock is up over 17.5% YTD.Actinium Pharmaceuticals Inc. (600% Jump in Message Volume)Actinium is launching trials for its drug Actimab-A in combination with Merck’s Keytruda and Bristol Myers Squibb’s Opdivo to treat solid tumors. The trials will include head-to-head studies comparing Actimab-A combinations to standalone treatments.&nbsp;The company also entered a research agreement with Memorial Sloan Kettering to expand Actimab-A’s applications.&nbsp;Actinium stock is up over 22% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week

Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

GCTK
GlucoTrack Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest GCTK News

GCTKGlucoTrack Inc